Zydus Lifesciences
Date : 23.02.2025
Zydus
Timeframe : Weekly
Strengths
1 Good profit growth of 32.60% for the Past 3 years.
2 Healthy Interest coverage ratio of 11.85.
3 Maintaining an effective average operating margins of 27.25% in the last 5 years.
4 Company’s PEG ratio is 0.16.
5 Has an efficient Cash Conversion Cycle of 45.65 days.
6 Company has a healthy liquidity position with current ratio of 2.22.
7 The company has a high promoter holding of 74.98%
Latest Update :
RECEIVES FINAL APPROVAL FROM USFDA FOR IBUPROFEN AND FAMOTIDINE TABLETS, 800 MG/26.6 MG
Regards,
Ankur
Zydus
Timeframe : Weekly
Strengths
1 Good profit growth of 32.60% for the Past 3 years.
2 Healthy Interest coverage ratio of 11.85.
3 Maintaining an effective average operating margins of 27.25% in the last 5 years.
4 Company’s PEG ratio is 0.16.
5 Has an efficient Cash Conversion Cycle of 45.65 days.
6 Company has a healthy liquidity position with current ratio of 2.22.
7 The company has a high promoter holding of 74.98%
Latest Update :
RECEIVES FINAL APPROVAL FROM USFDA FOR IBUPROFEN AND FAMOTIDINE TABLETS, 800 MG/26.6 MG
Regards,
Ankur
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。